Montenero A S, Mazzari M, Schiavoni G, Manzoli U, Gherardi S
Pharmatherapeutica. 1983;3(6):417-21.
An open study was carried out to assess the efficacy of indoramin used as second step therapy in 30 patients with moderate to severe hypertension who had failed to respond adequately to monotherapy with a thiazide or beta-blocker. After a 1-week washout period, patients started treatment with 25 mg indoramin twice daily plus hydrochlorothiazide (25 mg twice daily) or propranolol (40 mg once daily). Indoramin dosage was subsequently adjusted in 25 mg steps (to maximum 150 mg daily), if necessary, at follow-up control visits every 14 days. Analysis of the results from the 22 patients who completed the 75-day study period showed that there were progressive, statistically significant reductions in systolic and diastolic blood pressure (supine and erect) to clinically acceptable levels. Heart rate also decreased significantly and this was more evident in the 7 patients treated with the combination of indoramin, thiazide plus beta-blocker. No patient had orthostatic hypotension and few side-effects were reported, although 7 patients withdrew for this reason.
开展了一项开放性研究，以评估吲哚拉明作为第二步治疗药物，用于30例中度至重度高血压患者的疗效，这些患者对噻嗪类药物或β受体阻滞剂单一疗法反应欠佳。经过1周的洗脱期后，患者开始接受治疗，每日两次服用25mg吲哚拉明，加用氢氯噻嗪（每日两次25mg）或普萘洛尔（每日一次40mg）。随后，如有必要，在每14天的随访控制访视时，以25mg的剂量递增调整吲哚拉明剂量（最大每日150mg）。对完成75天研究期的22例患者的结果分析表明，收缩压和舒张压（仰卧位和直立位）均逐步出现具有统计学意义的显著降低，降至临床可接受水平。心率也显著下降，这在接受吲哚拉明、噻嗪类药物加β受体阻滞剂联合治疗的7例患者中更为明显。没有患者出现体位性低血压，报告的副作用也很少，尽管有7例患者因此退出研究。
